How Sangamo's Section 363 auction split its assets between two buyers
A bankruptcy auction split Sangamo's pipeline between two buyers.
The winning bid was more than four times the stalking-horse floor.
Sangamo Therapeutics filed for Chapter 11 bankruptcy protection on June 23, 2026. Six weeks later, its gene therapy programs found new owners anyway.
PTC Therapeutics and Eli Lilly are together paying $163.55 million in cash, plus up to $100 million more in milestones, for the assets Sangamo spent years building.
$163.55 million in cash. Up to $100 million more in milestones.
What was sold
On August 13, 2026, Sangamo completed a Section 363 asset auction, a bankruptcy court sale of a company's assets to the highest bidder. The main asset up for sale was an AAV gene therapy.
AAV is a virus with its disease-causing ability removed. It acts like a delivery van, carrying a working copy of a gene into a patient's cells.
Two buyers split the assets between them:
The deal, in numbers
- PTC Therapeutics is buying ST-920, Sangamo's investigational Fabry disease gene therapy, for $111 million upfront, plus up to $100 million in FDA-approval milestones (up to $80 million for accelerated approval, $20 million more for full approval). PTC plans to finish the regulatory application in Q4 2026 and could launch the therapy in 2027.
- Eli Lilly is buying Sangamo's underlying technology platforms — capsid delivery, zinc-finger gene editing, and MINT — along with its ST-506 prion disease program, for $50 million.
- Total deal value: $163.55 million in cash at closing, subject to court approval and standard closing conditions. The Lilly transaction is expected to close around September 4, 2026; the PTC transaction is pending review under the Hart-Scott-Rodino Antitrust Improvements Act.
Why this matters
Sangamo's bankruptcy was a failure of the company, not the science. Sangamo ran out of operating money before it could bring its programs to market on its own. That is a hard outcome for the people who built this work, and it deserves to be said plainly.
But the assets themselves stayed valuable. One was a clinical-stage Fabry disease gene therapy.
The other was a zinc-finger gene-editing platform (a tool for precisely editing genes) with over two decades of development behind it. Two separate pharmaceutical companies competed to buy them in a public auction.
That is the part worth remembering. Platform quality and company survival are two separate questions. A program can have excellent science behind it and still run out of money before it reaches an approved product.
Sangamo's technology did not lose value when the company went bankrupt. It simply changed hands. The science keeps moving forward because other companies, with more money behind them, were willing to bet on it.
Why PTC, why Lilly: the logic behind the bids
The clearest sign this wasn't a routine, pre-arranged sale is how much the price moved. In June, Sangamo lined up Astellas as the stalking-horse bidder (the opening bid that sets a floor) for ST-920, at $25 million upfront plus up to $25 million in milestones. TerSera Therapeutics was named as the backup bidder.
When the court-supervised auction opened on August 10, PTC's winning bid came in more than four times that floor: $111 million upfront plus up to $100 million in milestones.
More than four times the stalking-horse floor — a real market test, not an insider deal.
That gap matters. The real market price for a near-approval AAV gene therapy turned out to be far above what one insider bidder had offered a distressed seller. That argues against calling this a fire sale.
PTC's own leadership was direct about the logic. It has little to do with betting on unproven science. CEO Matthew Klein called it a "unique opportunity" that delivers "significant return on investment without the need for any development or commercial build," and said the deal "advances our strategy of leveraging our accomplished existing rare disease global commercial infrastructure to accelerate short- and intermediate-term revenue growth."
That infrastructure is real: PTC already sells eladocagene exuparvovec (Upstaza in Europe and the UK, Kebilidi in the US).
It is a one-time AAV gene therapy for AADC deficiency, another rare disease in children.
ST-920 looks a lot like it: one gene, one rare disease, one-time AAV treatment, already at BLA stage (the final application stage before FDA approval).
So PTC is not buying a new capability. It is adding a second product to sales and distribution machinery it has already built.
Lilly's $50 million purchase looks less like a grab for an interesting platform and more like turning an existing partnership into full ownership.
Lilly had already licensed Sangamo's neurotropic capsid, STAC-BBB (a viral delivery shell built to target nerve cells), in April 2025 for CNS-targeted gene delivery.
That deal was worth an $18 million upfront payment and up to $1.4 billion in potential milestones across five neurology targets.
Buying the capsid, zinc-finger, and MINT platforms plus the ST-506 prion disease program in August builds on a relationship Lilly had already tested.
It is not starting fresh with an unknown partner.
It also fits a wider pattern. Lilly paid up to $1.3 billion in 2025 to acquire Verve Therapeutics for its base-editing programs, after years of licensing deals with Verve and Beam Therapeutics. That is evidence Lilly has been shifting from licensing gene-editing technology to owning it outright.
One connection is worth flagging as unconfirmed: whether ST-506 has any stated link to Lilly's Alzheimer's franchise. No public Lilly statement ties the two together, so that stays an open question, not an assumption.
Sangamo's own deal history helps explain why two well-funded companies were willing to trust assets coming out of a bankrupt company. Pfizer carried Sangamo's zinc-finger hemophilia A gene therapy through Phase 3 before ending the collaboration in December 2024. Novartis and Biogen separately licensed the platform for neurological gene-regulation targets, and both of those partnerships also wound down in 2024.
Three large pharma companies had already spent years and real money studying this technology before stepping back. They left for portfolio reasons, not because of any disclosed safety or efficacy failure. PTC and Lilly were not taking a blind flyer on unproven science.
They were buying technology that had already survived multiple rounds of big-pharma scrutiny. It just hadn't earned big-pharma commitment, until now.
What this means for the patients waiting
Fabry disease is a rare, inherited disorder. The body cannot make enough of one enzyme it needs to break down a fatty substance.
Without that enzyme, the fatty substance builds up inside cells throughout the body. Over time, this causes chronic pain, worsening kidney damage, an enlarged heart, and a much higher risk of stroke.
For decades, there have been only two treatment options: enzyme replacement infusions every two weeks for life, or, for patients whose specific mutation qualifies, a daily pill. Both manage the disease.
Neither cures it.
Both require a lifelong, unbroken commitment to treatment just to hold the line.
A one-time gene therapy that gives the body a lasting, working copy of the missing gene offers something different.
It promises the chance at steady enzyme production, without a treatment routine that follows a patient for life. That is what ST-920 is being developed to do. PTC now owns the program, and PTC has the resources to carry it through regulatory review and, if approved, bring it to market.
For people living with Fabry disease right now, that is not an abstract detail. It is a chance at a genuinely different daily life.
This is also why it matters that Sangamo's zinc-finger platform did not disappear along with the company that built it. Gene-editing platforms take decades and huge amounts of money to reach clinical readiness. When one company runs out of money, the risk is not just to that company's shareholders.
Hard-won scientific progress can simply stall. Instead, two larger, well-funded companies chose to keep this platform moving forward.
That is a genuinely hopeful signal for the field. The science built by a struggling company can still reach the patients waiting for it, because someone else stepped in to finish the job.
What this means for other drug developers
The detail worth studying isn't the bankruptcy. It's what made Sangamo's assets sellable at all.
ST-920 survived because it was close to approval and simple in structure: one gene, one disease, one treatment. Sangamo's platforms survived because Lilly, Pfizer, Novartis, and Biogen had all already licensed pieces of them before the bankruptcy.
That meant three separate large pharma teams had already studied the underlying science closely, years earlier. Neither of those things happened by accident. Both are decisions a developer can make on purpose, long before a worst-case scenario is on the table.
That points to a concrete planning exercise: model what happens to your program if you run out of cash before approval, not just whether you might. A platform with no partners and no near-term product is hard for anyone to value, or move quickly on, in a distressed sale.
If you've solved a problem like this, Commercial & Strategy experts get matched to paid consulting work through GTC's Expert Network — join free.
A platform with an existing licensing deal has a built-in path to a next owner. So does a program close enough to approval that it can plug into someone else's sales and distribution machinery.
Licensing deals signed while a company is healthy aren't just non-dilutive capital (funding that doesn't require selling more equity). They are pre-installed exit ramps if the company itself doesn't make it.
The wider impact on the field
Zoom out, and this deal is a data point about how the whole field absorbs failure, not just about one company. Gene therapy has been through downturns before.
The more common pattern was a struggling company's programs going quiet instead of finding a new owner.
Funding dried up, trials paused, and platforms sat idle with no one stepping in. What happened to Sangamo is different.
A public, court-supervised auction produced two competing bids from established pharma companies.
The price was four times the insider floor, for technology that had already been in development for over two decades.
If that pattern holds beyond this one case, it says something the field badly needs to hear: platform-level gene and cell therapy technology has become recognized, transferable value. It is not a sunk cost that disappears when one company runs out of money.
The flip side is worth naming honestly too. Sangamo's capsid, zinc-finger, and MINT platforms now sit inside Lilly, one very large buyer, instead of an independent company that could license them out on its own terms.
Consolidation like this can mean faster, better-funded development. It can also mean fewer independent platform holders for smaller biotechs to license from. Both are true at once, and it's worth watching which one wins out as more of these deals happen.
Why investors should care
The way this auction played out is a useful data point for anyone pricing distressed biotech risk, not just this one company. A stalking-horse bid is meant to set a floor, not a fair price.
It usually stays close to that floor when nobody else shows up. Here, it didn't.
The gap between the insider offer and the winning bid shows that a real market exists for de-risked, late-stage biotech assets.
This includes assets whose parent company was wiped out in Chapter 11 bankruptcy. That matters for how investors model recovery value in distressed situations generally. It does not mean much for Sangamo's own shareholders, though: asset-sale proceeds go to the bankruptcy estate and its creditors first, so shareholders should not expect meaningful recovery.
The more lasting lesson is about the shape of the risk. A single-asset, near-approval program and a platform-only program with no partners carry very different downside risk, even at similar valuations.
One is easy to sell in a crisis. The other is much harder to move.
When evaluating earlier-stage gene and cell therapy companies, that difference is worth pricing in directly, instead of treating every clinical-stage biotech as the same all-or-nothing bet. At the sector level, this also matters.
19 large pharma acquisitions in six months, at a median deal size several times larger than the early-2020s norm, is a sign of strong buyer demand. That is worth factoring into what you expect an earlier-stage company to eventually sell for, right now, not just the ones already in distress.
The bigger picture: a busy year for gene therapy M&A
Sangamo isn't an isolated case. Biotech deal-making has picked up sharply in 2026.
HSBC Innovation Banking counted 19 large pharma acquisitions of biotechs in the first half of the year alone. That's more than any full calendar year in the last five, at a median deal value of roughly $950 million, about three times the typical size from the early 2020s.
The same week Sangamo's sale closed, Jazz Pharmaceuticals agreed to acquire Actio Bio for up to $1.32 billion (820 million upfront, up to 500 million in milestones).
The deal was for its Phase 1b/2a epilepsy candidate. These are two very different deal shapes: one a distressed-asset auction, the other a straightforward acquisition of a private company.
But both point the same direction. Large pharma is actively buying clinical-stage gene and cell therapy programs right now, not waiting for them to reach the market on their own.
What this means for a CGT program
PTC plans to finish the regulatory application for ST-920 in Q4 2026. A possible 2027 launch would follow if it is approved. That is a live budget line for anyone tracking what a BLA-stage rare-disease asset is worth to an acquirer.
GTC analysis: this is a budget and vendor decision, not a science one. Survival now depends less on data quality and more on whether there is enough runway to reach a buyer before the cash runs out. Build that model now, while you can still choose the terms.
GTC analysis: here, the unpartnered, near-approval route priced higher. PTC paid $111 million for ST-920 alone, against $50 million for Lilly's platform bundle, built on the capsid license it already held. A founder weighing the two exit routes should price that gap into the decision.
Frequently asked questions
What happened to Sangamo Therapeutics?
Sangamo Therapeutics filed for Chapter 11 bankruptcy protection on June 23, 2026. On August 13, 2026, it completed a court-supervised Section 363 asset auction.
It sold its main gene therapy programs and platforms to PTC Therapeutics and Eli Lilly for approximately $163.55 million in cash, plus up to $100 million in potential milestones.
What did PTC Therapeutics buy from Sangamo?
ST-920, Sangamo's investigational gene therapy for Fabry disease, for $111 million upfront plus up to $100 million in FDA-approval milestones.
What did Eli Lilly buy from Sangamo?
Sangamo's capsid delivery, zinc-finger gene editing, and MINT platforms, plus its ST-506 prion disease program, for $50 million.
Why did a bankrupt company's gene therapy assets attract buyers?
Because the bankruptcy reflected a company running out of capital, not a failure of its science. The underlying clinical data and platform technology were strong enough for two pharmaceutical companies to pay real money for them in a competitive auction.
Was the Sangamo auction competitive, or an insider deal?
It was competitive. PTC outbid Astellas (the original stalking-horse bidder at $25M + $25M in milestones) and TerSera Therapeutics, with a final offer more than four times the stalking-horse floor.
AAV to AI, Edition 02
Get the weekly resource
Three signals across four published stories, with decision context to help CGT teams act earlier.
Free PDF, 40 pages.
Download Edition 02Sources
- Sangamo Therapeutics: Selects Successful Bidders Following Competitive Asset Auction — press release, August 13, 2026
- PTC takes a chance on Sangamo's Fabry disease gene therapy — BioPharma Dive
- Sangamo Therapeutics, Inc. — Form 8-K (Exhibit 99.1) — U.S. Securities and Exchange Commission
- PTC's $211M bid wins Sangamo auction, teeing up 'special opportunity' to enter Fabry market — Fierce Biotech
- PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program — PTC Therapeutics Investor Relations
- Sangamo Therapeutics Announces Capsid License Agreement With Lilly — Sangamo Investor Relations, April 3, 2025
- Eli Lilly to acquire Verve Therapeutics for $1.3 billion — CNBC
- Sangamo Therapeutics to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizer's Decision to Cease Development — Sangamo Investor Relations
- Sangamo Therapeutics faces setbacks as Novartis and Biogen collaborations come to an end — MM+M
- Jazz to buy rare epilepsy drugmaker in potentially $1.3B deal — BioPharma Dive
- Biotech funding rises 75% this year as M&A activity continues — Investing.com
Join the GTC Expert Network
Independent Experts
Independent experts in cell & gene therapy: share knowledge, help build a report, or contribute quietly. Build authority and get called for paid consulting work. Join free.
Early R&D Experts
Early R&D ExpertsContribute target validation, vector engineering, or transgene design expertise. Get matched to paid consulting work through content you help create.
Join FreeCMC Experts
CMC ExpertsContribute scale-up, tech transfer, or GMP manufacturing expertise. Get matched to paid consulting work through content you help create.
Join FreeRegulatory Affairs Experts
Regulatory Affairs ExpertsContribute IND/BLA strategy or regulatory liaison expertise. Get matched to paid consulting work through content you help create.
Join FreeCommercial & Strategy Experts
Commercial & Strategy ExpertsContribute due diligence, licensing, or market access expertise. Get matched to paid consulting work through content you help create.
Join FreeEnabling Technology Experts
Enabling Technology ExpertsContribute bioprocessing hardware, analytical tooling, or supply-chain expertise. Get matched to paid consulting work through content you help create.
Join FreeAI Transformation Experts
AI Transformation ExpertsContribute agentic workflow, LLM, or AI-driven vector design expertise. Get matched to paid consulting work through content you help create.
Join FreeIndustry Representatives
Industry professionals in cell & gene therapy: de-risk your pipeline with expert input on demand, exactly when your program needs it. Join free.
Drug Developers
Drug DevelopersFounders, CSOs, VPs of R&D
Practical guides spanning vector design through commercialization, plus direct access to the expert network that wrote them.
Join FreeInvestors / VCs
Investors / VCsVC Fund Managers, Family Offices, Angels
Due diligence frameworks and strategic intelligence for evaluating CGT assets, from experts who do this diligence for a living.
Join FreeTechnology Developers
Technology DevelopersFounders, Licensing & Commercial Leads
IP protection and platform strategy guides for enabling technologies, plus the network that built them.
Join FreeCDMOs / CROs
CDMOs / CROsBD, Operations & Technical Leads
Partner selection, vendor evaluation, and operational excellence guides, sourced from the CGT organisations that use them.
Join FreeVendors / Suppliers
Vendors / SuppliersCommercial & Technical Leads
Market intelligence and partnership strategies for supply chain companies serving cell and gene therapy.
Join FreeStrategy Consultants
Strategy ConsultantsConsultants, Market Access Advisors
Spot the problems before they cost your clients — join the network that shapes what GTC covers next.
Join FreeAI Transformation Partners
AI Transformation PartnersAI/ML Consultancies, Digital Transformation Firms
AI education, implementation, and consulting for operational excellence in cell and gene therapy — for companies building or buying AI capability.
Join FreeWhere the analysis comes from. Industry teams get expert input on demand; independent experts build authority and get called for paid consulting work.
See more of our work in Google Search
Google lets you pick the sites you want to see more often in Top Stories. Add Gene Therapy Consultancy to your list, and our daily gene therapy news will show up higher for you.